Recital 2, Regulation (EU) 2024/2699

In forcesince 18 Oct 2024

The Commission is to lay down rules for the implementation of Regulation (EU) 2021/2282 as regards the cooperation, in the form of exchange of information, of the Coordination Group and the Commission acting as secretariat of the Coordination Group (‘the HTA secretariat’) with the European Medicines Agency and with the expert panels designated in accordance with Article 106(1) of Regulation (EU) 2017/745 of the European Parliament and of the Council [Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p. 1, ELI: http://data.europa.eu/eli/reg/2017/745/oj).] relevant for the joint work referred to in Articles 7 to 21 of Regulation (EU) 2021/2282. Pursuant to Article 30 of Regulation (EU) 2022/123 of the European Parliament and of the Council [Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (OJ L 20, 31.1.2022, p. 1, ELI: http://data.europa.eu/eli/reg/2022/123/oj).], the European Medicines Agency is acting as secretariat for those expert panels. Therefore, the cooperation with the expert panels provided for in this Implementing Regulation should be conducted via the European Medicines Agency.